Full-Time

Director of Clinical Operations

Posted on 5/13/2026

Tr1X

Tr1X

11-50 employees

Develops cellular immunotherapies for autoimmune diseases

Compensation Overview

$206k - $225k/yr

+ Discretionary annual target bonus + Incentive stock options

San Diego, CA, USA

In Person

On-site in San Diego, CA; travel up to 15%.

Category
Biology & Biotech (1)
Requirements
  • Bachelor’s degree in a scientific or healthcare-related discipline with a minimum of 10 years of progressive clinical operations experience, including at least 5 years of direct sponsor clinical study management and leadership experience
  • Demonstrated leadership experience managing complex global or multi-center clinical trials across multiple phases of development
  • Experience in cell and/or gene therapy clinical trials preferred, particularly within Multiple Sclerosis, Inflammatory Bowel Disease, or other autoimmune indications
  • Extensive working knowledge of ICH/GCP guidelines, FDA regulations, and global clinical trial regulatory requirements
  • Proven ability to lead cross-functional teams, influence stakeholders, and drive strategic clinical operations initiatives in a fast-paced environment
  • Strong operational leadership skills with demonstrated expertise in study start-up, trial execution, vendor oversight, risk management, and inspection readiness
  • Experience supporting pre-NDA programs and Phase 1 first-in-human clinical trials, including operational strategy, study oversight, monitoring, and close-out activities
  • Advanced experience with clinical trial systems including eClinical Trial Management System, Electronic Trial Master File, EDC, safety databases, and other clinical technologies
  • Exceptional strategic thinking, problem-solving, organizational, communication, and executive presentation skills
  • Ability to independently manage competing priorities while leading within a matrixed cross-functional organizational structure
  • Demonstrated success mentoring and developing high-performing clinical operations teams
  • High level of professionalism, integrity, accountability, and business acumen
  • Legally authorized to work for any employer in the United States
  • Travel up to 15%
  • The position is based on-site in San Diego, California.
Responsibilities
  • Provide strategic leadership as the Clinical Study Lead for cross-functional teams to ensure study start-up, enrollment, maintenance, and close-out activities are executed on schedule, within budget, and in accordance with quality expectations
  • Direct and oversee all aspects of clinical study management to ensure operational excellence, inspection readiness, and delivery of high-quality clinical data
  • Lead the clinical operational development, review, and finalization of clinical trial protocol synopses, protocols, protocol amendments, and other key study-related documents
  • Lead the CRO and vendor selection strategy for outsourced activities, including RFP development, bid management, proposal evaluation, budget negotiations, and executive-level vendor selection decisions
  • Direct negotiation, execution, and oversight of contracts and scopes of work with CROs, study vendors, consultants, and investigative sites
  • Oversee the development and maintenance of critical study documents, including informed consent templates, management plans, study trackers, and operational plans, ensuring appropriate delegation and accountability
  • Chair and lead internal and external clinical study meetings, governance reviews, and cross-functional operational discussions, ensuring alignment of objectives, decisions, and action items
  • Partner strategically with Regulatory Affairs to ensure timely preparation and submission of site essential regulatory documentation to the FDA and other regulatory authorities
  • Develop and oversee clinical monitoring strategies and monitoring plans to ensure compliance, quality oversight, and operational consistency across studies and vendors
  • Provide strategic oversight for case report form (CRF) design, edit check development, and data collection methodologies in partnership with Data Management and Clinical Development
  • Lead site initiation planning and execution activities, including oversight of training materials, presentations, and investigator engagement strategies
  • Provide leadership and governance oversight of CROs, field monitors, and clinical vendors to ensure contractual obligations, quality metrics, and operational deliverables are achieved
  • Establish oversight processes for monitoring visit reports, protocol deviations, CAPAs, and action item resolution to ensure quality and compliance standards are maintained
  • Direct and oversee study-wide operational activities including vendor management, biospecimen handling, investigational product logistics, investigator payments, data quality oversight, and centralized records management
  • Lead the review and analysis of clinical data reports to identify operational, safety, and efficacy trends and communicate findings to cross-functional leadership and governance committees
  • Ensure Trial Master File oversight and inspection readiness throughout the duration of all assigned studies
  • Lead and facilitate internal clinical program meetings, investigator meetings, safety review committees, and other cross-functional governance forums
  • Partner with departmental leadership to define and execute clinical development operational strategies, resource planning, and process optimization initiatives
  • Proactively identify operational risks and implement mitigation strategies to ensure study continuity, compliance, and successful execution
  • Travel to clinical sites, investigator meetings, and vendor locations as required, up to 15%
  • Foster a culture of accountability, collaboration, operational excellence, and continuous improvement within a fast-paced, dynamic clinical development environment
  • Perform additional strategic and operational responsibilities as required to support evolving business and clinical development objectives
Desired Qualifications
  • Experience in cell and/or gene therapy clinical trials preferred, particularly within Multiple Sclerosis, Inflammatory Bowel Disease, or other autoimmune indications

Tr1X focuses on cellular immunotherapies for autoimmune and inflammatory diseases. Using a proprietary platform, it creates first-in-class cell therapy products that aim to rebalance the immune system and restore homeostasis, achieving long-term tolerance. The company develops and commercializes these therapies, generating revenue through partnerships, licensing, and direct sales, with a business base in La Jolla, CA. How it works: the core product is a cell therapy designed to modulate immune responses so the body reaches stable immune balance rather than ongoing suppression. This differs from many competitors by emphasizing durable immune tolerance via a proprietary platform and by pursuing partnerships and licensing to bring therapies to healthcare providers and patients. The goal is to deliver durable immune tolerance for autoimmune and inflammatory diseases through first-in-class cell therapies.

Company Size

11-50

Company Stage

Early VC

Total Funding

$125M

Headquarters

San Diego, California

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA cleared INDs for TRX103 in GvHD and TRX319 in MS, trials advancing with positive safety data.
  • Secured $75M Series A from Column Group and $50M financing plus $8M CIRM grant.
  • San Diego biotech hub provides talent access near UCSD and 400+ local companies.

What critics are saying

  • Manufacturing scale-up fails, halting TRX103 and TRX319 GMP production within 12-24 months.
  • TRX319 Phase 1 triggers cytokine release safety signal, terminating MS program in 6-18 months.
  • Regeneron and AstraZeneca displace Tr1X with faster Treg efficacy readouts in 18-36 months.

What makes Tr1X unique

  • Tr1X engineers allogeneic Tr1 Treg cells mimicking natural Tr1 cells for superior inflammation homing.
  • Proprietary platform enables scalable off-the-shelf CAR-Treg therapies like TRX319 for progressive MS.
  • Founded on Dr. Maria Grazia Roncarolo's Tr1 cell discovery, first in clinical trials.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Tr1X who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

401(k) Company Match

Flexible Work Hours

Stock Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

2%
San Diego Business Journal
Oct 27th, 2025
Tr1X Bio Secures $50M Funding

Tr1X Bio, based in San Diego, received FDA approval for IND status for TRX319, aimed at treating progressive multiple sclerosis. The company secured $50M in financing to support clinical trials for TRX319, set to begin next year. Tr1X's technology, based on research by Dr. Maria Grazia Roncarolo, uses allogeneic cells to treat autoimmune diseases. The company also advances TRX103 for graft vs. host disease and Crohn's disease, backed by an $8M CIRM grant.

GlobeNewswire
Oct 14th, 2025
Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis, and $50 Million in Additional Financing

Tr1X announced the FDA has cleared its IND application for TRX319 in progressive multiple sclerosis and a $50M financing that extends its runway into...

Clinical Trial Vanguard
Apr 7th, 2025
TR1X Awarded $8M Grant for TRX103 GvHD Trial

TR1X awarded $8M grant for TRX103 GvHD trial.

Benzinga
Apr 4th, 2025
Tr1X Awarded $8 Million Cirm Grant To Support Trx103 Phase 1/2A Clinical Trial For Graft-Versus-Host Disease

SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced "Trix"), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell therapies with the potential to cure autoimmune and inflammatory diseases, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded the Company an $8 million grant to support its ongoing Phase 1/2a clinical trial of TRX103, an engineered Tr1 Treg cell therapy for use in the prevention of graft-versus-host disease (GvHD) in blood cancer patients undergoing mismatched stem cell transplants. This award follows a $4 million CIRM grant received by Tr1X in early 2024 for late-stage preclinical research that helped to advance TRX103 to human trials. The TRX103 Phase 1/2a clinical trial is being led by Maria Grazia Roncarolo, MD, co-founder, president and head of RD at Tr1X, with patients enrolling at leading stem cell transplant centers across the country. The trial is designed to treat patients receiving a mismatched or haploidentical transplant with a one-time infusion of TRX103. The Company has reported positive initial persistence and safety data in the first two patient cohorts, with additional data anticipated to be reported in 2025

TMCnet
Apr 4th, 2025
Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease

Tr1X is developing TRX103 for the treatment of several immune and inflammatory disorders.

INACTIVE